

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10658873	
	Filing Date		2003-09-05	
	First Named Inventor	Michael S. Kopreski		
	Art Unit	1634		
	Examiner Name	Lu, Frank Wei Min		
	Attorney Docket Number	00-1312-K		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10658873
Filing Date		2003-09-05
First Named Inventor	Michael S. Kopreski	
Art Unit	1634	
Examiner Name	Lu, Frank Wei Min	
Attorney Docket Number	00-1312-K	

1	Vitetta et al. (1991), "Immunotoxins," In: Biologic Therapy of Cancer, (Ed. DeVita et al.) Lippincott: Philadelphia pp. 482-495.	<input type="checkbox"/>
2	Wang et al. (1989), "Quantitation of mRNA by the polymerase chain reaction," Proc. Natl. Acad. Sci. U. S. A. 86: 9717-9721.	<input type="checkbox"/>
3	Wieczorek et al. (1987), Cancer Research 47: 6407-6412.	<input type="checkbox"/>
4	Wieczorek et al. (1989), Schweiz med Wschr 119: 1342-1343.	<input type="checkbox"/>
5	Wieczorek et al. (1985), Proc. Natl. Acad. Sci. U. S. A. 82: 3455-3459.	<input type="checkbox"/>
6	Wiedmann et al. (1994), PCR Methods Applic. 3: 551-564.	<input type="checkbox"/>
7	Yanuck et al. (1993), Cancer Research 52: 3257-3261.	<input type="checkbox"/>
8	Rohde et al. (2000), Clin. Cancer Res. 6: 4803-4809.	<input type="checkbox"/>
9	Keller et al. (1993), PCR Methods and Applications 3: 32-38.	<input type="checkbox"/>
10	Nolte et al. (1994), J. Clin. Microbiology 32: 519-520.	<input type="checkbox"/>
11	Schmidt et al. (1995), J. Med. Virology 47: 153-160.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10658873
Filing Date		2003-09-05
First Named Inventor	Michael S. Kopreski	
Art Unit		1634
Examiner Name	Lu, Frank Wei Min	
Attorney Docket Number		00-1312-K

12	Agliullina et al. (1988), Eksp. Onkol (USSR) 10(4), English abstract.	<input type="checkbox"/>
13	Schwarz et al. (1995), Res. Virol (Paris) 146(5), English abstract.	<input type="checkbox"/>
14	Kato et al. (1993), Hepatology 18(1), abstract.	<input type="checkbox"/>
15	Glick et al. (1994), Molecular biotechnology: Principles and applications of recombinant DNA, ASM Press: Washington DC. Table of Contents for Molecular Diagnostics (8) and Vaccines and Therapeutic Agents (9).	<input type="checkbox"/>
16	Persing et al (1993), Diagnostic molecular microbiology: Principles and applications, Amer. Soc. Microbiol. Washington DC, Table of Contents for Principles of Diagnostic Molecular Microbiology and Viral Pathogens.	<input type="checkbox"/>
17	Southall et al. (1990), Br. J. Cancer 61: 89-95.	<input type="checkbox"/>
18	Kopreski et al. (2001), Ann. N. Y. Acad. Sci 945: 172-178.	<input type="checkbox"/>
19	Yan-Sanders et al. (2002), Cancer Letters 183: 215-220.	<input type="checkbox"/>
20	Khimani et al. (2005), BioTechniques 38: 739-745.	<input type="checkbox"/>
21	Schrader et al. (2002), BMC Cancer 2: 32.	<input type="checkbox"/>
22	Fleischhacker et al. (2001), Ann. N. Y. Acad. Sci. 945: 179-188.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10658873
Filing Date		2003-09-05
First Named Inventor	Michael S. Kopreski	
Art Unit		1634
Examiner Name	Lu, Frank Wei Min	
Attorney Docket Number		00-1312-K

23	Burd et al. (1989), Proc. Natl. Acad. Sci. U. S. A. 86: 9788-9792.	<input type="checkbox"/>
24	Burchill et al. (1995), Br. J. Cancer 71: 278-281.	<input type="checkbox"/>
25	Lasheeb et al. (1997), Genitourinary Medicine 73(4): 303-305.	<input type="checkbox"/>
26	Mermin et al. (1991), J. Infectious Diseases 164(4): 769-772.	<input type="checkbox"/>
27	Kopreski et al. (2001), Clin. Chem. 47: 362, abstract 9.	<input type="checkbox"/>
28	Pelosi et al. (2006), Virchows Arch. 448: 7-15.	<input type="checkbox"/>
29	Tahara et al. (1999), Oncogene 18: 1561-1567.	<input type="checkbox"/>
30	Dasi et al. (2001), Lab. Investigation 81: 767-769.	<input type="checkbox"/>
31	Hasselmann et al. (2001), Oncol. Rep. 8: 115-118.	<input type="checkbox"/>
32	Ng et al. (2002), Clin. Chem. 48: 1212-1217.	<input type="checkbox"/>
33	Chen et al. (2000), Clin. Cancer Res. 6: 3823-3826.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10658873
Filing Date		2003-09-05
First Named Inventor	Michael S. Kopreski	
Art Unit	1634	
Examiner Name	Lu, Frank Wei Min	
Attorney Docket Number	00-1312-K	

34	Silva et al. (2001), Clin. Cancer Res. 7: 2821-2825.	<input type="checkbox"/>
35	Silva et al. (2001), Oncol. Rep. 8: 693-696.	<input type="checkbox"/>
36	Gal et al. (2001), Ann. N. Y. Acad. Sci. 945: 192-194.	<input type="checkbox"/>
37	Durie et al. (2000), Acta Oncol. 39: 789-796.	<input type="checkbox"/>
38	Miura et al. (2003), Oncology 64: 430-434.	<input type="checkbox"/>
39	Wong et al. (2004), J. Clin. Pathol. 57: 766-768.	<input type="checkbox"/>
40	Ma et al. (2007), Haematologica 92: 170-175.	<input type="checkbox"/>
41	Arcari et al. (1984), Nucleic Acids Res. 12: 9179-9189.	<input type="checkbox"/>
42	Rykova et al. (2006), Ann. N. Y. Acad. Sci. 1075: 328-333.	<input type="checkbox"/>
43	Hernandez et al. (1999), Leukemia 13: 2087-2093.	<input type="checkbox"/>
44	Zhou et al. (1998), Clin. Cancer Res. 4: 1631-1640.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10658873
	Filing Date		2003-09-05
	First Named Inventor	Michael S. Kopreski	
	Art Unit	1634	
	Examiner Name	Lu, Frank Wei Min	
	Attorney Docket Number	00-1312-K	

	45	Zhou et al. (2001), Breast Cancer Research and Treatment 66: 217-224.	<input type="checkbox"/>
	46	Press et al. (1990), Oncogene 5: 953-962.	<input type="checkbox"/>
	47	Ng et al. (2003), Proc. Natl. Acad. Sci. U. S. A. 100: 4748-4753.	<input type="checkbox"/>
	48	Bairey et al. (2002), Arch. Pathol. Lab. Med. 126: 574-576.	<input type="checkbox"/>
	49	Gilmour et al. (2001), Cancer Res. 61: 2169-2716.	<input type="checkbox"/>
	50	Reinhold et al. (2001), Clin. Chem. 47: 369, abstract 50.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.